Nektar(US:NKTR) Prnewswire·2026-03-18 13:15Core Viewpoint - Nektar Therapeutics is facing a securities class action lawsuit due to alleged misrepresentations regarding patient enrollment compliance in its pivotal REZOLVE-AA clinical trial, which has resulted in significant investor losses [1][4][6]. Group 1: Lawsuit Details - The class action seeks to recover damages for investors who purchased Nektar securities between February 26, 2025, and December 15, 2025 [2]. - Nektar's shares fell by $4.14, or 7.77%, closing at $49.16 on December 16, 2025, after the company disclosed that four patients with major study eligibility violations were included in the REZOLVE-AA trial [3]. - Investors have until May 5, 2026, to seek lead plaintiff status in the lawsuit [3]. Group 2: Clinical Trial Enrollment Issues - The REZOLVE-AA trial required strict patient screening criteria, including a SALT score between 50 and 100, stable disease for at least six months, and completion of an eight-week washout period from prior medications [3]. - The lawsuit claims that Nektar failed to enforce these standards, resulting in the randomization of four ineligible patients, which represented over 4% of the total 94 patients randomized in the study [4][5]. - The trial's primary endpoint narrowly missed statistical significance when including the ineligible patients, with p-values of 0.186 and 0.121 for the two dosing arms [5]. Group 3: Management's Misrepresentation - Nektar management allegedly misled investors by repeatedly assuring them that enrollment followed applicable instructions and protocol standards, despite the enrollment failures [5][6]. - The complaint highlights a significant gap between Nektar's representations about its enrollment procedures and the actual occurrences at its trial sites [4][6]. - The integrity of Nektar's clinical enrollment process is called into question, as shareholders were not provided with accurate information regarding the trial's compliance with protocols [7].